Guideline- Versus Non-Guideline-Based Neoadjuvant Management of Clinical T4 Rectal Cancer
Current Oncology · 21.10.2023 · 30 (10) · 9346-9356
DOI: 10.3390/curroncol30100676 ↗Kurz gefasst
Leitlinie in der Zeitschrift Current Oncology, online erschienen am 21.10.2023. Verfasst von Xi Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastrointestinal Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Rectal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the West China Hospital of Sichuan University.
Abstract (Originalsprache)
(1)
Background
Practice guidelines recommend neoadjuvant treatment for clinical T4 rectal cancer. The primary objective of this retrospective study was to assess whether compliance with guidelines correlates with patient outcomes. Secondarily, we evaluated predictors of adherence to guidelines and mortality. (2)
Methods
A total of 397 qualified rectal cancer (RC) patients from 2017 to 2020 at West China Hospital of Sichuan University were included. Patients were divided into two groups depending on adherence to neoadjuvant treatment guidelines. The main endpoints were overall survival (OS) and disease special survival (DSS). We analyzed factors associated with guideline adherence and mortality. (3)
Results
Compliance with guidelines was only 39.55%. Patients’ neoadjuvant therapy treated not according to the guidelines for clinical T4 RC was not associated with an overall survival (95.7% vs. 88.9%) and disease special survival (96.3% vs. 91.1%) benefit. Patients were more likely to get recommended therapy with positive patient compliance. Staging Ⅲ, medium/high differentiation and objective compliance were associated with increased risk of mortality. (4)
Conclusions
Guideline adherence for clinical T4 RC in our system is low. Compliance with the relevant guidelines for neoadjuvant therapy seems not to lead to better overall survival for patients with clinical T4 RC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastrointestinal Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu 610041, China.
- West China School of Medicine, West China Hospital of Sichuan University, Chengdu 610041, China.
- Colorectal Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China.
ORCID-Profile: Xiaodong Wang
Förderung
- the West China Hospital of Sichuan University
Zitieren
APA
Chen, X., Xie, X., Wang, X., Wei, M., Li, Z., & Li, L. (2023). Guideline- Versus Non-Guideline-Based Neoadjuvant Management of Clinical T4 Rectal Cancer. Current Oncology, 30(10), 9346-9356. https://doi.org/10.3390/curroncol30100676
Vancouver
Chen X, Xie X, Wang X, Wei M, Li Z, Li L. Guideline- Versus Non-Guideline-Based Neoadjuvant Management of Clinical T4 Rectal Cancer. Current Oncology. 2023;30(10):9346-9356. doi:10.3390/curroncol30100676
BibTeX
@article{Chen2023,
author = {Chen, Xi and Xie, Xinyu and Wang, Xiaodong and Wei, Mingtian and Li, Zhigui and Li, Li},
title = {Guideline- Versus Non-Guideline-Based Neoadjuvant Management of Clinical T4 Rectal Cancer},
journal = {Current Oncology},
year = {2023},
volume = {30},
number = {10},
pages = {9346--9356},
doi = {10.3390/curroncol30100676}
}
EUVIMED